Aptamer Sciences Inc (KOSDAQ:291650)

Market Cap	29.25B
Revenue (ttm)	286.36M
Net Income (ttm)	-9.42B
Shares Out	29.28M
EPS (ttm)	-554.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	382,199
Average Volume	657,919
Open	1,050.00
Previous Close	1,015.00
Day's Range	951.00 - 1,050.00
52-Week Range	842.00 - 4,015.00
Beta	0.43
RSI	44.03
Earnings Date	n/a

About Aptamer Sciences

Aptamer Sciences Inc, a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. The company’s platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics for cancer and neurological disorders. It offers AlloMAp and Bi-Functional Aptame (BiFAp) platform programs for therapeutics, as well as Aptodetect-lung, an early diagnosis kit for lung cancer. Aptamer Sciences Inc was founded in 2011 and is headquartered in Seongnam-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 291650

Financial Performance

In 2023, Aptamer Sciences's revenue was 243.19 million, a decrease of -32.12% compared to the previous year's 358.25 million. Losses were -13.60 billion, 91.2% more than in 2022.